Supplementary data

Nitric Oxide-Scavenging Hyaluronic Acid Nanoparticles for Osteoarthritis Treatment

Yunyoung Nah^a, Sivasangu Sobha^b, Gurusamy Saravanakumar^b, Byung-Yoon Kang^b, Joo-Byoung Yoon^b, Won Jong Kim^{*a,b,c}

^a Department of Chemistry, POSTECH-CATHOLIC Biomedical Engineering Institute, POSTECH, Pohang 37673, South Korea

^b OmniaMed Co., Ltd, Pohang 37666, Republic of Korea

° School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and

Technology (POSTECH), Pohang 37673, South Korea

*Corresponding author

E-mail address: wjkim@postech.ac.kr

Table S1. IC₅₀ values of HA, NSc, HA-NSc, and HA + NSc mixture against LPS (-) and LPS (+) RAW 264.7 cells.

IC ₅₀	НА	NSc	HA + NSc	HA-NSc
LPS (-) RAW 264.7	-	0.659 ± 0.012	0.447 ± 0.010	1.27 ± 0.045
LPS (+) RAW 264.7	-	0.438 ± 0.009	0.460 ± 0.007	1.352 ± 0.173



Fig. S1 The ¹H NMR in DMSO- d_6 and ESI-MS spectra of compound 2.



Fig. S2 The ¹H NMR in DMSO- d_6 and ESI-MS spectra of compound 3.



Fig. S3 The ¹H NMR in DMSO- d_6 and ESI-MS spectra of NSc.



Fig. S4 The ¹H NMR spectrum of HA-NSc conjugate in DMSO- d_6/D_2 O. The asterisks indicate solvent residual peak.



Fig. S5 The GPC spectra of HA ($M_n = 100\ 000\ g/mol$) and HA-NSc conjugate.



Fig. S6 TEM images of HA (scale bar = 200 nm). Nanoparticles were not observed.



Fig. S7 The decomposition of (A) HA and (B) HA-NSc conjugate was confirmed through GPC after incubation with NO solution of different concentrations for 24 h.



Fig. S8 NO responsiveness of NSc and HA-NSc conjugate. ¹H NMR spectra of (A) NSc and (B) HA-NSc conjugate before and after incubation with NO solution. UV-Vis absorption spectra of (C) Nsc and (D) HA-NSc conjugate before and after incubation with NO solution.



Fig. S9 Confirmation of NO scavenging abilities of (A) HA, (B) NSc, (C) HA + NSc mixture and (D) HA-NSc conjugate according to their concentration (n = 5, mean \pm SD).



Fig. S10 Measurement of the rapeutic effect of HA-NSc NPs in MIA-induced OA rat model. (A) Paw with drawal latency and (B) weight bearing measurements during monitoring period $(n = 5, \text{mean} \pm \text{SEM}, *p < 0.05, **p < 0.01, ***p < 0.001).$



Fig. S11 Body weight measurements of each groups on Day 3, Day 14, and Day 21 after MIA injection (n = 5, mean \pm SD).



Fig. S12 (A) Immunohistochemical staining images of IL-1 β of isolated joints after monitoring (scale bar = 100 µm) and (B) their quantitative analysis (n = 3, mean \pm SD).